ArticleJournal of clinical medicine2023

Risankizumab Therapy for Moderate-to-Severe Psoriasis-A Multi-Center, Long-Term, Real-Life Study from Poland.

Michał Adamczyk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.